Corinna A. Kulicke

Apr 24, 2024 | nature.com | Mike B. Barnkob |Yale Michaels |Philip Macklin |Uzi Gileadi |Salvatore Valvo |Margarida Rei | +14 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-47424-z, published online 12 April 2024In this article the title was incorrectly written as ‘Semmaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells’ but should have been ‘Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells’. The original article has been corrected.

Apr 12, 2024 | nature.com | Yale Michaels |Philip Macklin |Uzi Gileadi |Salvatore Valvo |Margarida Rei |Corinna A. Kulicke | +14 more

AbstractSemaphorin-3A (SEMA3A) functions as a chemorepulsive signal during development and can affect T cells by altering their filamentous actin (F-actin) cytoskeleton. The exact extent of these effects on tumour-specific T cells are not completely understood. Here we demonstrate that Neuropilin-1 (NRP1) and Plexin-A1 and Plexin-A4 are upregulated on stimulated CD8+ T cells, allowing tumour-derived SEMA3A to inhibit T cell migration and assembly of the immunological synapse.

Feb 23, 2024 | nature.com | Corinna A. Kulicke |Gwendolyn M. Swarbrick |Aneta H. Worley |Fikadu Tafesse |Andrew Olive |William Hildebrand | +5 more

AbstractMR1-restricted T cells have been implicated in microbial infections, sterile inflammation, wound healing and cancer. Similar to other antigen presentation molecules, evidence supports multiple, complementary MR1 antigen presentation pathways. To investigate ligand exchange pathways for MR1, we used MR1 monomers and tetramers loaded with 5-(2-oxopropylideneamino)-6-d-ribitylaminouracil (5-OP-RU) to deliver the antigen.